Aquestive Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aquestive announced positive results from human factors validation and pharmacokinetic studies for Anaphylm (dibutepinephrine) sublingual film conducted to address FDA Complete Response Letter received January 2026. Revised packaging reduced median pouch-opening time from 17 to 3 seconds; incorrect film placement dropped from 20 to 2 participants (out of 105–166); self-administered PK was comparable to clinician-administered; top-of-tongue misplacement showed clinically meaningful pharmacodynamic response. Company plans NDA resubmission in Q3 2026.
Why this rating
Major near-term catalyst for pipeline asset worth potentially hundreds of millions if approved; resolves regulatory objections; resubmission Q3 2026 is <8 months away.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.